GC Cell said it plans to present two research findings at the upcoming Society for Immunotherapy of Cancer (SITC 2024), scheduled to take place from Nov. 6 to 10 in Houston, Texas, the U.S.
Founded in 1984, SITC is the world’s largest immunotherapy conference, attracting over 4,600 experts from more than 70 countries.
The presentations will highlight the company's progress in developing its NK cell therapy candidate, GCC4001 (cord blood NK Cell), and the combination therapy of GCC4001 with the EGFR-targeted monoclonal antibody, Merck KGaA’s Erbitux (ingredient: cetuximab).
According to GC Cell, GC Cell’s preclinical study, conducted using an animal model of head and neck cancer, demonstrates that the combination therapy of GCC4001 and Erbitux nearly doubles the anti-cancer effect compared to Erbitux monotherapy.
In addition to these findings, GC Cell will also unveil its proprietary NK cell expansion technique based on eHuT-78 CDV feeder cells, which is expected to offer a significant competitive advantage in the production and cultivation of NK cells for therapeutic use.
Through its participation at SITC and poster presentations, GC Cell aims to showcase its technological prowess and competitiveness on the global stage while establishing strategic networks for potential collaborations and partnerships.